NPPA writes to UT over 1,000% margin on medicines

CHANDIGARH: Drug price regulator National Pharmaceutical Pricing Authority (NPPA) replied to the UT health department after it came to fore that the MRPs of a few medicines not under its price control had exceeded 1,000% margin.

The letter from NPPA was in response to a complaint of increased MRPs of three cough syrups. The anomaly was detected by UT health secretary Yashpal Garg.
Prior to taking action against the manufacturers, NPPA found that they had not submitted Form V, which is required to compare the hike as price escalation of more than 10% annually is not permitted.

The NPPA has asked the Parwanoo-based manufacturers to explain why the form was not submitted by the end of the month.
The mandate of NPPA is to ensure that drug prices are compliant with the Drugs (Prices Control) Order, 2013.
“The formulations contained in MCAIN, RICAINE & SUFIT-O brands are non-scheduled formulations under DPCO, 2013 and prices for the same are not fixed by NPPA. For non-scheduled formulations, manufacturers are at liberty to fix initial prices,” mentioned the letter from NPPA deputy director

Saurabh Bansal to the UT health secretary.
It added, “The manufacturers/marketers mentioned in your letter have not submitted Form-V to NPPA, as required under DPCO, 2013. Changes in MRP since 2013 are required to examine compliance with Para 20 of DPCO, 2013. Accordingly, these manufacturers/ marketers have been directed to submit the requisite data separately.”

Related Posts

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Draft bill proposes powers for DIs to inspect online pharmacy office premises

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

Delhi DCA mandates digital tracking for controlled substances on new DMS portal

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?